COMMUNIQUÉS West-GlobeNewswire

Leap Therapeutics Announces First Patient Dosed with TRX518 Combination Therapy in Advanced Solid Tumors Trial
16/01/2018
CAMBRIDGE, Mass., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq: LPTX ), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that the first patient has been [...]
MPX Appoints New Chief Financial Officer
16/01/2018
TORONTO, Jan. 16, 2018 (GLOBE NEWSWIRE) -- MPX Bioceutical Corporation (the “ Company ” or “ MPX ”) (CSE:MPX) (OTC:MPXEF) is pleased to announce the appointment of David McLaren as the Company’s new Chief Financial [...]
Cambrex & AstraZeneca Hold Ceremony to Mark Long-Term Supply Agreement at Karlskoga, Sweden Facility
16/01/2018
EAST RUTHERFORD, N.J., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM ), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today held an opening [...]
Anavex Life Sciences Reports Potential Normalization of Hypertension with ANAVEX®2-73 Published in The Journal of Clinical Hypertension
16/01/2018
NEW YORK, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL ), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of [...]
Exergen Gears Up for Severe Cold and Flu Season
16/01/2018
WATERTOWN, Mass., Jan. 16, 2018 (GLOBE NEWSWIRE) -- As Australia’s flu season predicted earlier this year, North America is beginning to see the effects of a high intense flu season. The main flu strain for 2017-18 is [...]
Antares Pharma Provides XYOSTED™ Regulatory Update
16/01/2018
EWING, N.J., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS ) today announced that a Type A meeting has been scheduled with the U.S. Food and Drug Administration (FDA) on February 21, 2018 for [...]
Clean energy for Bio-on's new biopolymers "factory" thanks to a trigeneration plant built by Gruppo Hera
16/01/2018
Bologna, 16 January 2018 - Bio-on , the leader in eco-sustainable chemical technologies, and Gruppo Hera, one of Italy's main multi-utility providers, have reached an agreement for the supply of clean energy thanks to [...]
Une énergie propre pour la nouvelle « usine » de bio-polymères Bio-on, grâce à une installation tri-génératrice réalisée par Gruppo Hera
16/01/2018
Bologne, 16 janvier 2018 - Bio-on , société leader du secteur des technologies pour la chimie écologique, et Gruppo Hera , une des principales sociétés Multi-utility italiennes, ont conclu un accord de fourniture d'une [...]
Motif Bio Receives Award from Cystic Fibrosis Foundation
16/01/2018
NEW YORK, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Motif Bio® plc (AIM:MTFB) (NASDAQ: MTFB ), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has [...]
Sales of Olainfarm Last Year Increased by at Least 4%
16/01/2018
Olaine, 2018-01-16 07:46 CET (GLOBE NEWSWIRE) -- December 2017, consolidated sales Sales, thsnd. EUR Changes to December 2016 Share in total sales Russia 4 471 -12% 44% Latvia 2 682 -2% 27% Ukraine 840 700% 8% Belarus [...]
Half-Year Report on DBV Technologies Liquidity Contract with Natixis
16/01/2018
AMF REGULATED INFORMATION Montrouge, France, January 16, 2018 Half-Year Report on DBV Technologies Liquidity Contract with Natixis Under the liquidity contract between DBV TECHNOLOGIES and NATIXIS, the following assets [...]
Bilan semestriel du contrat de liquidité DBV Technologies contractés avec Natixis
16/01/2018
Informations Réglementées Montrouge, France, le 16 janvier 2018, (7H30 CET) Bilan semestriel du contrat de liquidité DBV Technologies contractés avec Natixis Montrouge, France le 12 janvier 2018 - Au titre du contrat de [...]
ESPERITE (ESP) : L1 Capital subscribes to the 13th tranche of investment today
16/01/2018
Amsterdam, The Netherlands - 16 January 2018 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the 13 th Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the " [...]
Novartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients
16/01/2018
Results from CLARITY study show Cosentyx ® (secukinumab) was significantly more effective than Stelara ®* (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks [1] Data support findings [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
16/01/2018
REGULATED INFORMATION GHENT, Belgium, 16 January 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
16/01/2018
REGULATED INFORMATION GHENT, Belgium, 16 January 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
NEOVACS : STRENGTHENED ITS INTELLECTUAL PROPERTY IN RUSSIA
16/01/2018
NEOVACS STRENGTHENED ITS INTELLECTUAL PROPERTY IN RUSSIA This patent covers IFNalpha kinoid and its application in all diseases related to an overproduction of IFNalpha cytokine Paris and Boston, January 16 th 2018, 07: [...]
NEOVACS : RENFORCE SA PROPRIÉTÉ INTELLECTUELLE EN RUSSIE
16/01/2018
NEOVACS RENFORCE SA PROPRI É T É INTELLECTUELLE EN RUSSIE Ce brevet porte sur l'IFNalpha Kinoïde et son utilisation dans les maladies liées à la surproduction de la cytokine IFNalpha Paris et Boston, le 16 janvier 2018 [...]
Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA
16/01/2018
Adalimumab is an anti-TNF medicine used to treat a range of immunological diseases[1] The comprehensive data package provided is expected to demonstrate that Sandoz proposed biosimilar adalimumab matches the reference [...]

Pages